Literature DB >> 16138345

Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia.

Elliott Vichinsky1, Ellen Butensky, Ellen Fung, Mark Hudes, Elizabeth Theil, Linda Ferrell, Roger Williams, Leslie Louie, Phillip D K Lee, Paul Harmatz.   

Abstract

Although it is life saving, transfusion therapy has resulted in the majority of sickle cell anemia and thalassemia patients being at risk for hemosiderosis-induced organ damage. It is unknown whether the complications of iron overload are affected by the underlying disease. In order to address this problem, we compared the prevalence of organ dysfunction in both groups of patients receiving chronic transfusion therapy (beta thalassemia, N = 30; sickle cell anemia, N = 43). Both groups had similar quantitative liver iron. Thalassemia patients had greater cardiac disease (20% vs. 0%), growth failure (27% vs. 9%), and endocrine failure (37% vs. 0%). The strongest predictors of combined endocrine and cardiac disease in multivariate analysis were duration of chronic transfusion (P = 0.03) and diagnosis (P = 0.03). Quantitative liver iron concentration on a single liver biopsy was not predictive of cardiac or endocrine injury. Viral hepatitis is the strongest predictor of hepatocellular damage (P = 0.009), while the development of liver fibrosis is more closely related to liver iron concentration (P = 0.04). In conclusion, sickle cell anemia and thalassemia differ in the prevalence of organ injury. This difference is related to the duration of iron exposure and the specific hemoglobinopathy. A prospective study with a larger number of subjects is needed to confirm the relationships between specific diagnosis, liver iron concentration over time, and organ dysfunction. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138345     DOI: 10.1002/ajh.20402

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  41 in total

1.  Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

Authors:  Patrick B Walter; Ellen B Fung; David W Killilea; Qing Jiang; Mark Hudes; Jacqueline Madden; John Porter; Patricia Evans; Elliott Vichinsky; Paul Harmatz
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

2.  Erythropoietic drive is the strongest predictor of hepcidin level in adults with sickle cell disease.

Authors:  Matthew S Karafin; Kathryn L Koch; Amy B Rankin; Debora Nischik; Ghady Rahhal; Pippa Simpson; Joshua J Field
Journal:  Blood Cells Mol Dis       Date:  2015-07-17       Impact factor: 3.039

Review 3.  Transfusion in Haemoglobinopathies: Review and recommendations for local blood banks and transfusion services in Oman.

Authors:  Arwa Z Al-Riyami; Shahina Daar
Journal:  Sultan Qaboos Univ Med J       Date:  2018-04-04

4.  Severe cardiac iron toxicity in two adults with sickle cell disease.

Authors:  Hellen Oduor; Caterina P Minniti; Alessandra Brofferio; Ahmed M Gharib; Khaled Z Abd-Elmoniem; Matthew M Hsieh; John F Tisdale; Courtney D Fitzhugh
Journal:  Transfusion       Date:  2016-12-26       Impact factor: 3.157

Review 5.  Iron-chelating therapy for transfusional iron overload.

Authors:  Gary M Brittenham
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

6.  Practical implications of liver and heart iron load assessment by T2*-MRI in children and adults with transfusion-dependent anemias.

Authors:  Sarah Deborah Chirnomas; Marnix Geukes-Foppen; Kristen Barry; Jennifer Braunstein; Leslie A Kalish; Ellis J Neufeld; Andrew J Powell
Journal:  Am J Hematol       Date:  2008-10       Impact factor: 10.047

Review 7.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

8.  Iron overload in sickle cell disease.

Authors:  Radha Raghupathy; Deepa Manwani; Jane A Little
Journal:  Adv Hematol       Date:  2010-05-17

9.  Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease.

Authors:  Nilesh R Ghugre; Ignacio Gonzalez-Gomez; Ellen Butensky; Leila Noetzli; Roland Fischer; Roger Williams; Paul Harmatz; Thomas D Coates; John C Wood
Journal:  Am J Hematol       Date:  2009-08       Impact factor: 10.047

10.  Bilirubin cholelithiasis and haemosiderosis in an anaemic pyruvate kinase-deficient Somali cat.

Authors:  C van Geffen; K Savary-Bataille; K Chiers; U Giger; S Daminet
Journal:  J Small Anim Pract       Date:  2008-08-05       Impact factor: 1.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.